Pathos news and milestones

Pathos Communications reported first-half 2026 revenue of $7.3 million, up 14% year over year, while adjusted EBITDA increased 36% to $1.7 million as the PR technology company ex…

Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.

NEW YORK, August 3rd, 2026 (GLOBE NEWSWIRE) - Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing ag…

Pathos assumes responsibility for early clinical development of AZD4241, utilizing its AI-driven Foundry platform to drive patient stratification and trial design.…

AI-powered drug development startup Pathos AI closes $365M investment - SiliconANGLE

New York, NY, May 8th, 2025 (GLOBE NEWSWIRE) - Pathos AI, (www.pathos.com), a leading AI-enabled biotech company focused on transforming drug development in oncology, today annou…

AstraZeneca has started work with Tempus and Pathos AI on a $200m project to build a comprehensive multimodal foundation model for oncology.

CHICAGO, April 23, 2025 - Pathos AI, Inc.(www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, toda…

CHICAGO, Mar. 20, 2025 (GLOBE NEWSWIRE) - Pathos AI, (www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intell…

Chicago - Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning to transfo…

NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (

Pathos obtains worldwide rights from Novo Nordisk for the development of CBP/p300 inhibitor, FT-7051 Chicago - Pathos AI, Inc. (www.pathos.com), a biotechnology c…